Increasing inclusion of patients with advanced chronic kidney disease in cardiovascular clinical trials

Kidney Int. 2018 Apr;93(4):787-788. doi: 10.1016/j.kint.2017.11.028.

Authors

Roy O Mathew¹, Sripal Bangalore², Mandeep S Sidhu³, Jerome L Fleg⁴, Franklin W Maddux⁵

Affiliations

¹ University of South Carolina School of Medicine, WJB Dorn VAMC, Columbia, South Carolina, USA. Electronic address: roy.mathew@va.gov.
² New York University School of Medicine, New York, New York, USA.
³ Albany Medical College and Albany Medical Center, Albany, New York, USA.
⁴ National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA.
⁵ Fresenius Medical Care North America, Waltham, Massachusetts, USA.

PMID: 29571453
DOI: 10.1016/j.kint.2017.11.028

No abstract available

MeSH terms

Cardiovascular Diseases / diagnosis
Cardiovascular Diseases / epidemiology
Cardiovascular Diseases / physiopathology
Cardiovascular Diseases / therapy*
Humans
Kidney / physiopathology
Patient Selection*
Randomized Controlled Trials as Topic / methods*
Renal Insufficiency, Chronic / diagnosis
Renal Insufficiency, Chronic / epidemiology
Renal Insufficiency, Chronic / physiopathology
Renal Insufficiency, Chronic / therapy*
Risk Factors
Treatment Outcome